Inovio Pharmaceuticals, Inc.
General ticker "INO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $138.3M (TTM average)
Inovio Pharmaceuticals, Inc. does not follow the US Stock Market performance with the rate: -8.5%.
Estimated limits based on current volatility of 6.7%: low 1.20$, high 1.37$
Factors to consider:
- Total employees count: 134 (+9.8%) as of 2024
- Top business risk factors: Significant losses, Supply chain disruptions, Litigation risks, Acquisition/divestiture risks, Poor capital deployment decisions
- Price in estimated range
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.28$, 3.76$]
- 2026-12-31 to 2027-12-31 estimated range: [1.47$, 4.09$]
Financial Metrics affecting the INO estimates:
- Positive: with PPE of -1.7 at the end of fiscal year the price was neutral
- Negative: Operating cash flow per share per price, % of -8.82 <= 0.02
- Negative: negative Operating income
- Positive: 19.44 < Shareholder equity ratio, % of 32.43 <= 42.58
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Investing cash flow per share per price, % of 1.40 > -0.63
Short-term INO quotes
Long-term INO plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.83MM | $0.22MM | $0.07MM |
| Operating Expenses | $144.77MM | $112.62MM | $86.89MM |
| Operating Income | $-143.94MM | $-112.40MM | $-86.82MM |
| Non-Operating Income | $13.53MM | $5.14MM | $1.88MM |
| Interest Expense | $1.22MM | $0.18MM | $0.00MM |
| R&D Expense | $86.68MM | $75.62MM | $54.21MM |
| Income(Loss) | $-130.41MM | $-107.25MM | $-84.95MM |
| Profit(Loss)* | $-135.12MM | $-107.25MM | $-84.95MM |
| Stockholders Equity | $117.35MM | $68.50MM | $24.10MM |
| Assets | $170.95MM | $113.20MM | $74.31MM |
| Operating Cash Flow | $-124.37MM | $-104.08MM | $-88.63MM |
| Capital expenditure | $0.32MM | $0.49MM | $0.29MM |
| Investing Cash Flow | $87.36MM | $104.07MM | $14.04MM |
| Financing Cash Flow | $5.00MM | $51.48MM | $53.05MM |
| Earnings Per Share** | $-6.09 | $-3.95 | $-0.18 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.